

HR 3091

MODDERN Cures Act of 2013

Congress: 113 (2013–2015, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 12, 2013

Current Status: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

Latest Action: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet. (Oct 15, 2013)

Official Text: <https://www.congress.gov/bill/113th-congress/house-bill/3091>

Sponsor

Name: Rep. Lance, Leonard [R-NJ-7]

Party: Republican • **State:** NJ • **Chamber:** House

Cosponsors (16 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Ellison, Keith [D-MN-5]	D · MN		Sep 12, 2013
Rep. Guthrie, Brett [R-KY-2]	R · KY		Sep 12, 2013
Rep. Jones, Walter B., Jr. [R-NC-3]	R · NC		Sep 12, 2013
Rep. King, Peter T. [R-NY-2]	R · NY		Sep 12, 2013
Rep. Loebsack, David [D-IA-2]	D · IA		Sep 12, 2013
Rep. Long, Billy [R-MO-7]	R · MO		Sep 12, 2013
Rep. Lujan, Ben Ray [D-NM-3]	D · NM		Sep 12, 2013
Rep. McCaul, Michael T. [R-TX-10]	R · TX		Sep 12, 2013
Rep. Paulsen, Erik [R-MN-3]	R · MN		Sep 12, 2013
Rep. Rangel, Charles B. [D-NY-13]	D · NY		Sep 12, 2013
Rep. Roskam, Peter J. [R-IL-6]	R · IL		Sep 12, 2013
Rep. Runyan, Jon [R-NJ-3]	R · NJ		Sep 12, 2013
Rep. Schwartz, Allyson Y. [D-PA-13]	D · PA		Sep 12, 2013
Rep. Tiberi, Patrick J. [R-OH-12]	R · OH		Sep 12, 2013
Rep. Walden, Greg [R-OR-2]	R · OR		Sep 12, 2013
Rep. Buchanan, Vern [R-FL-16]	R · FL		Oct 2, 2013

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Sep 13, 2013
Judiciary Committee	House	Referred to	Oct 15, 2013
Ways and Means Committee	House	Referred To	Sep 12, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
113 HR 3116	Related bill	Jan 9, 2014: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
113 HR 2085	Related bill	Jun 3, 2013: Referred to the Subcommittee on Health.

Summary (as of Sep 12, 2013)

Modernizing Our Drug & Diagnostics Evaluation and Regulatory Network Cures Act of 2013 or MODDERN Cures Act of 2013 - Requires the Secretary of Health and Human Services (HHS) to: (1) establish the Advanced Diagnostics Education Council to recommend standard terms and definitions related to innovative diagnostics for use by patients, physicians, health care providers, payers, and policy makers; and (2) publish a guide regarding such terms and definitions.

Sets forth additional factors for the Secretary to consider in determining the payment amount for new clinical diagnostic laboratory tests under gap filling procedures which are used when no comparable existing test is available.

Extends the exclusivity period for a medicine if the diagnostic test related to such drug has been determined by the Secretary to have been developed by, or with the participation of, the manufacturer or sponsor of the medicine, and use of the diagnostic tests provides for or improves: (1) the identification of a patient population for the medicine; or (2) the determination of the most appropriate treatment option for a patient population with the medicine.

Establishes a dormant therapy designation for medicine that addresses unmet medical needs. Gives such medicine 15 years of data exclusivity under which no drug can be approved by relying on the approval or licensure of the dormant therapy.

Directs the Secretary to arrange with the Institute of Medicine (or, if it declines, another appropriate entity) to study intellectual property laws and their impact on therapy and diagnostic development in order to formulate recommendations on how to facilitate the clinical evaluation and development of therapies currently available on the market for new potential indications.

Actions Timeline

- **Oct 15, 2013:** Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
- **Sep 13, 2013:** Referred to the Subcommittee on Health.
- **Sep 12, 2013:** Introduced in House
- **Sep 12, 2013:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.